SELLAS Life Sciences Receives Fast Track Designation from
- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL...
Angelos Stergiou Bruce Mackle Genfleet Therapeutics Shanghai Inc Drug Administration Memorial Sloan Kettering Cancer Center Life Sciences Group Inc
Source: globenewswire.com